He Li-Mei, Borjigin Sarul, Chen Xin-Qi, Yan Zhao-Li, Wang Ming-Jie
Department of Internal Medicine, Inner Mongolia Medical University, Hohhot 010000, Inner Mongolia Autonomous Region, China.
Department of Endocrinology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010000, Inner Mongolia Autonomous Region, China.
World J Diabetes. 2025 May 15;16(5):101509. doi: 10.4239/wjd.v16.i5.101509.
Diabetic retinopathy (DR), a leading cause of visual loss, is the result of microvascular damage induced by prolonged hyperglycemia. Numerous studies have revealed the pivotal role of integrins in the pathogenesis of DR, particularly in key processes such as inflammation, vascular leakage, microthrombus formation, and angiogenesis. Consequently, targeting integrins is considered a promising strategy for the treatment of DR. This review focuses on the function of integrins in DR and their potential as therapeutic targets. It describes the molecular mechanisms through which integrins influence DR progression and summarizes the latest outcomes of integrin antagonist-based therapeutic strategies in clinical studies, evaluating their efficacy and potential challenges, which offer promise as novel treatment options for DR.
糖尿病视网膜病变（DR）是视力丧失的主要原因，是长期高血糖诱导的微血管损伤的结果。大量研究揭示了整合素在DR发病机制中的关键作用，特别是在炎症、血管渗漏、微血栓形成和血管生成等关键过程中。因此，靶向整合素被认为是治疗DR的一种有前景的策略。本综述重点关注整合素在DR中的功能及其作为治疗靶点的潜力。它描述了整合素影响DR进展的分子机制，并总结了基于整合素拮抗剂的治疗策略在临床研究中的最新成果，评估了它们的疗效和潜在挑战，这些为DR提供了新的治疗选择。
